Product Description
Bright Peak has engineered an enhanced IL-2 cytokine harboring specific modifications to amino acid side chains to uniquely block binding to IL2Rbeta and simultaneously enhance binding to IL2Ralpha, creating an IL-2 mutein that preferentially expands and activates Tregs. Bright Peak’s IL-2 autoimmune cytokine payload can also be conjugated to antibodies as part of their Immunocytokine platform. It is a PEG-IL2 AID (Sourced from: https://brightpeaktx.com/pipeline/)
Mechanisms of Action: IL2 Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bright Peak Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Autoimmune Disease Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|